Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.
2.

Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.

Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ, Lee B, Pastan I.

Cancer Res. 2001 Jul 1;61(13):5070-7.

3.

Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.

Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, Pastan I.

J Immunol. 2000 Dec 15;165(12):7150-6.

4.
7.

Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.

Benhar I, Padlan EA, Jung SH, Lee B, Pastan I.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12051-5.

8.
9.

Recombinant single-chain immunotoxins against T and B cell leukemias.

Kreitman RJ, Pastan I.

Leuk Lymphoma. 1994 Mar;13(1-2):1-10. Review.

PMID:
8025511
10.

Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.

Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I.

Bioconjug Chem. 1993 Mar-Apr;4(2):112-20.

PMID:
7873642
11.
13.

Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor.

Saito T, Kreitman RJ, Hanada S, Makino T, Utsunomiya A, Sumizawa T, Arima T, Chang CN, Hudson D, Pastan I, et al.

Cancer Res. 1994 Feb 15;54(4):1059-64.

PMID:
8313362
15.

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I.

Clin Cancer Res. 2005 Feb 15;11(4):1545-50.

16.
17.

B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I.

Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8616-20.

18.

Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.

Hexham JM, Dudas D, Hugo R, Thompson J, King V, Dowling C, Neville DM Jr, Digan ME, Lake P.

Mol Immunol. 2001 Sep;38(5):397-408.

PMID:
11684296
19.

In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells.

Nagai T, Tanaka M, Tsuneyoshi Y, Matsushita K, Sunahara N, Matsuda T, Yoshida H, Komiya S, Onda M, Matsuyama T.

Arthritis Rheum. 2006 Oct;54(10):3126-34.

20.

Supplemental Content

Support Center